Romatoid Artrit Hastalarında İnsülin Direnci ve Metabolik Sendrom Sıklığı

Symmons DP. Epidemiology of rheumatoid arthritis: determinants of onset, persistence and outcome. Best Pract Res Clin Rheumatol 2002; 16(5): 707-22.

Bacon PA, Moots RJ. Extra-articular rheumatoid arthritis. In: Kopman WJ (Ed). Arthritis and Allied Conditions. 13th Ed, Pennsylvania: Williams and Wilkins 1997; 71: 1088.

Dedhia HV, DiBartolomeo A. Rheumatoid arthritis. Review. Crit Care Clin 2002; 18: 841-54.

Sattar N, McCarey WD, Capell H. Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003; 108: 2957- 63.

Mutru O, Laakso M, Isomaki H, Koota K. Cardiovascular mortality in patients with rheumatoid arthritis. Cardiology 1989; 76: 71-7.

Masharani U, Karam JH, Germen MS. Pancreatic hormones and diabetes mellitus. In: Greenspan FS, Gardner DG, editors. Basic and Clinical Endocrinology. 7th ed. New York: The McGraw-Hill Companies 2004; 646-58.

Henry RR. Insulin Resistance: From predisposing factor to therapeutic target in type 2 diabetes. Clin Ther 2003; 25(suppl): 47-63.

Nilsson S. Research contributions of Eskil Kylin Sven Med Tidskr 2001; 5(1): 15-28.

Enzi G, Busetto L, Inelmen EM, Coin A, Sergi G. Historical perspective: visceral obesity and related comorbidity in Joannes Baptista Morgagni's 'De Sedibus et Causis Morborum per Anatomen Indagata' Int Journ of Obesity 2003; 27: 534–5.

Chung CP, Avalos I, Oeser A, Gebretsadik T, Shintani A, Raggi P, et al. High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors. Ann Rheum Dis 2007; 66: 208–14.

Rho YH, Choi SJ, Lee YH, Ji JD, Choi KM, Baik SH, et al. The prevalence of metabolic syndrome in patients with gout: a multicenter study. J Korean Med Sci 2005; 20: 1029–33.

Boyer GS, Lanier AP, Templin DW. Prevalence rates of spondyloarthropathies, rheumatoid arthritis, and other rheumatic disorders in an Alaskan Inupiat Eskimo population. J Rheumatol 1988; 15(4): 678-83.

Hochberg MC. Adult and juvenile rheumatoid arthritis: Current epidemiologic concepts. Epidemiol Rev 1981; 3: 27-44.

Spector TD. Rheumatoid arthritis. Rheum Dis Clin North Am 1990; 16(3): 513-37.

Beasley RP, Bennett PH, Lin CC. Low prevalence of rheumatoid arthritis in Chinese. Prevalence survey in a rural community. J Rheumatol 1983; (10 Suppl): 11-5.

Minaur N, Sawyers S, Parker J, Darmawan J. Rheumatic disease in an Australian 7-6- Aboriginal comminuty in North Queensland, Australia. A WHO-ILAR COPCORD study. J Rheumatol 2004; 31(5): 965-72.

MacGregor AJ, Snieder H, Rigby AS. Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum 2000; 43(1): 30-7.

Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. JAMA 1949; 140: 659-62.

Bergstrom G, Bjelle A, Sorensen LB, Sundh V, Svanborg A. Prevalence of rheumatoid arthritis, osteoarthritis, chondrocalcinosis and gouty arthritis at age 79. J Rheumatol 1986; 13(3): 527-34.

Hochberg MC. Changes in the incidence and prevalence of rheumatoid arthritis in England and Wales, 1970-1982. Semin Arthritis Rheum 1990; 19(5): 294-302.

Criswell LA, Merlino LA, Cerhan JR, et al. Cigarette smoking and the risk of rheumatoid arthritis among postmenopausal women: results from the Iowa Women's Health Study. Am J Medicine 2002; 112: 465-71.

Huizinga TW. Genetics in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2003; 17(5): 70316.

Stastny P. Association of the B-cell alloantigen DRw4 with rheumatoid arthritis. N Engl J Med 1978; 298(16): 869-71.

Siman AJ, Pearson JE. Epidemiology and genetics in rheumatoid arthritis. Arthritis Res 2002; 4(suppl 3): 265-72.

Weyand CM. New insights into the pathogenesis of rheumatoid arthritis. Rheumatology 2000; 39(suppl 1): 3-8.

Goronzy JJ, Zettl A, Weyand CM. T cell receptor repertoire in rheumatoid arthritis. Int Rev Immunol 1998; 17: 339-63.

Inman RD. Infectious etiology of rheumatoid arthritis. Rheum Dis Clin North Am 1991; 17(4): 859-70.

Van Der Heijde IM, Wilbrink B, Tchetverikov I. Presence of bacterial and bacterial proteoglycans in the joints of patients with rheumatoid arthritis and other arthritides. Arthritis Rheum 1998; 41: 162.

Hoffman RW, O'Sullivan FX, Schafermeyer KR. Mycoplasma infection and rheumatoid arthritis: Analysis of their relationship using immunobloting and ultrasensitive PCR detection method. Arthritis Rheum 1997; 40: 1219.

Depper JM, Zvaifer NJ. Epstein-Barr virus: Is relationship to the pathogenesis of rheumatoid arthritis. Arthritis Rheum 1981; 24(6): 755-61.

Balandraud N, Meynard JB, Auger I, Sovran H. Epstein-Barr virus load in the peripheral polymerase chain reaction. Arthritis Rheum 2003; 48(5): 1223-8.

Cohen BJ, Buckley MM, Clewley JP, Jones VE. Human parvovirus infection in early rheumatoid and inflammatory arthritis. Ann Rheum Dis 1986; 45(10): 832-8.

Nikkari S, Luukkainen R, Mottonen T, Meurman O. Does parvovirus B19 have a role in rheumatoid arthritis? Ann Rheum Dis 1994; 53(2): 106-11.

Lechner F, Vogt HR, Seow HF. Expression of cytokine mRNI in lentovirus-induced arthritis. Am J Pathol 1997; 151: 1053.

Olsen NJ, Kovacs WJ. Hormones, pregnancy, and rheumatoid arthritis. J Gend Specif Med 2002; 5(4): 28-37.

Spector TD, Roman E, Silman AJ. The pill, parity, and rheumatoid arthritis. Arthritis Rheum 1990; 33(6): 782-9.

Silman A, Kay A, Brennan P. Timing of pregnancy in relation to the onset of rheumatoid arthritis. Arthritis Rheum 1992; 35(2): 152-5.

Persellin RH. The effect of pregnancy on rheumatoid arthritis. Bull Rheum Dis 1976- 77; 27(9): 922-7.

Brennan P, Silman A. Breast-feeding and the onset of rheumatoid arthritis. Arthritis Rheum 1994; 37(6): 808-13.

Merlino LA, Cerhan JR, Criswell LA, Mikuls TR, Saag KG. Estrogen and other female reproductive risk factors are not strongly associated with the development of rheumatoid arthritis in elderly women. Semin Arthritis Rheum 2003; 33(2): 72-82.

Drossaers-Bakker KW, Zwinderman AH, van Zeben D, Breedveld FC, Hazes JM. Pregnancy and oral contraceptive use do not significantly influence outcome in long term rheumatoid arthritis. Ann Rheum Dis 2002; 61(5): 405-8.

Bresnihan B. Preventing joint damage as the best measure of biologic drug therapy. J Rheumatol 2002; 29(65) :39-43.

Hale LP, Haynes BF. Pathology of rheumatoid arthritis and associated disorders. In Koopman WJ (ed). Arthritis and allied conditions. Lippincott Williams and Wilkins, Philadelphia 2001; 1103-27.

Strand V, Kavanaugh AF. The role of interleukin-1 in bone resorption in rheumatoid arthritis. Rheumatology (Oxford) 2004; 43(Suppl-3): III10-III16.

Dayer JM. The process of identifying and understanding cytokines: from basic studies to treating rheumatic diseases. Best Pract Res Clin Rheum 2004; 18(1): 31-45.

Martel W, Hayes JT, Duff IF. The pattern of bone erosion in the hand and wrist in rheumatoid arthritis. Radiology 1965; 84: 204-14.

Goldring SR. Bone and joint destruction in rheumatoid arthritis: what is really happening? J Rheumatol 2002; 29 Suppl 65: 44-8.

Oelzner P, Franke S, Muller A, Hein G, Stein G. Relationship between soluble markers of immune activation and bone turnover in post-menopausal women with rheumatoid arthritis. Rheumatology (Oxford) 1999; 38(9): 841-7.

Lohmander LS, Hoerrner LA, Lark MW. Metalloproteinases, tissue inhibitors and proteoglycan fragments in knee synovial fluid in human osteoarthritis. Arthritis Rheum 1993; 36: 181-9.

Jofe I, Epstein S. Osteoporosis associated with rheumatoid arthritis: pathogenesis and management. Semin Arthritis Rheum 1991; 20: 256-72.

Deodhar AA, Woolf AD. Bone mass measurement and bone metabolism in rheumatoid arthritis: A review. Br J Rheumatol 1996; 35: 309-22.

Woolf AD. Osteoporosis in rheumatoid arthritis-the critical view point. Br J Rheumatol 1991; 30: 82-4.

Brown FE, Brown ML. Long-term results after tenosynovectomy to treat the rheumatoid hand. J Hand Surg 1988; 13- A(5): 704-8.

Abhilash J, Fionula B, Jagdeep N. Treatment of rheumatoid tenosynovitis with cytokine inhibitors. Lancet 2002; 360: 1565-6.

Hagena FW, Hofmann GO, Mittlmeier T, Wasmer G, Bergmann M. The cruciate ligaments in knee replacement. Int Orthop 1989; 13(1): 13-6.

Neurath MF. Detection of Luse bodies, spiralled collagen, dysplastic collagen, and intracellular collagen in rheumatoid connective tissues: an electron microscopic study. Ann Rheum Dis 1993; 52(4): 278-84.

Wada M, Imura S, Baba H, Shimada S. Knee laxity in patients with osteoarthritis and rheumatoid arthritis. Br J Rheumatol 1996, 35: 560-3.

Recklies AD, Poole AR, Banerjee S. Pathophysiologic aspects of inflammation in diarthrodial joints. In Buckwalter JA, Einhorn TA, Simon SR (eds). Orthopaedic Basic Science, American Academy of Orhopaedic Surgeons, Park Ridge, IL 2000; 489-530.

Abramson SB, Amin A. Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage. Rheumatology 2002; 41: 972-80.

Johnson LL, Dyer R, Hupe DJ. Matrix metalloproteinases. Curr Opin Chem Biol 1998; 37: 466-71.

Nietfeld JJ, Wilbrink B, Helle M. Interleukin-1-induced interleukin-6 is required for the inhibition of proteoglycan synthesis by interleukin-1 in human articular cartilage. Arthritis Rheum 1990; 33(11): 1695-701.

Hauselmann HJ, Flechtenmacher J, Michal L. The superficial layer of human articular cartilage is more susceptible to interleukin-1-induced damage than the deeper layers. Arthritis Rheum 1996; 39: 478-88.

Firestein GS. Invasive fibroblast-like synovicytes in rheumatoid arthritis. Passive responders or transformed aggressors. Arthritis Rheum 1996; 39: 1781-90.

Bresnihan B. Pathogenesis of joint disease in RA. J Rheumatol 1999; 26(3): 717-9.

Burmester GR, Stuhlmuller B, Keyszer G, Kinne RW. Mononuclear phagocytes and rheumatoid arthritis. Mastermind or workhorse in arthritis? Arhritis Rheum 1997; 40: 5- 18.

Hochberg MC, Chane RW, Dwosh I. The ACR 1991 revised criteria for the classification of the global functional status in rheumatoid arthritis. Arthritis Rheum 1992; 25: 498-502.

Arnett FC, Edworth SM, Bloch DA. The ARA 1987 revised criteria for classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.

Van der Heijde DMFM. Radiographic imaging: the "gold standard" for assesment of disease progression in theumatoid arthritis. Rheumatology 2000; 39(suppl 1): 9-16.

Graudal N. The natural history and prognosis of rheumatoid arthritis: association of radiographic outcome with process variables, joint motion and immune proteins. Scand J Rheumatol 2004; 118: 1-38.

Kaarela K, Kautiainen H. Continuous progression of radiological destruction in seropositive rheumatoid arthritis. J Rheumatol 1997; 24(7): 1285-7.

De Carvalho A, Graudal H, Jorgensen B. Radiologic evaluation of the progression of rheumatoid arthritis. Acta Radiol Diagn 1980; 21(1): 115-21.

Sculco TP. The knee joint in rheumatoid arthritis. Rheum Dis Clin North Am 1998; 24(1): 143-56.

Magyar E, Talerman A, Feher M, Wouters HW. The pathogenesis of the subchondral pseudocyst in rheumatoid arthritis. Clin Orthop 1974; 100: 341-8.

Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. JAMA 1949; 140: 59-62.

Conaghan PG, McGonagle D, Wakefield R, Emery P. New approaches in imaging of early rheumatoid arthritis. Clin Exp Rheumatol 1999; 17(6 suppl 18): 37-42.

Chen TS, Crues JV 3rd, Ali M, Troum OM. Magnetic resonance imaging is more sensitive than radiographs in detecting change in size of erosions in rheumatoid arthritis. J Rheumatol 2006; 33(10): 1957-67.

Gonzalez-Juanatey C, Testa A, Garcia-Castelo A, Garcia-Porrua C, Llorca J, Gonzalez- Gay MA. Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody. Arthritis Rheum 2004; 51: 447-50.

Gonzalez-Juanatey C, Gonzalez-Gay MA. Long-term rheumatoid arthritis and endothelial dysfunction. Atherosclerosis 2004; 176: 197-8.

Hurlimann D, Forster A, Noll G, Enseleit F, Chenevard R, Distler O, et al. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002; 106: 2184-7.

Salonen JT, Salonen R. Ultrasonographically assessed carotid morphology and the risk of coronary heart disease. Arterioscler Thromb 1991; 11:1245-9. Sattar N, McCarey DW, Capell H, McInnes IB inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003; 108: 2957- 63.

ACR 2008 Recommmendations, Arthritis& Rheum 2008.

Grundy, SM, Cleeman, JI, Daniels, SR. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112:2735. (2001 kriterlerinin UPDATE'i)

Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group The metabolic syndrome-a new worldwide definition. Lancet 2005; 366(9491): 1059-62.

The pathogenesis of atherosclerosis. In Braunwald E, Fauci A, Kasper D, Hauser S, Longo Dan L, Jameson Larry J (Eds.). Harrison’s principles of internal medicine15th ed. New York: Mc Graw Hill Co 2001; 1377-86.

Martel W, Hayes JT, Duff IF. The pattern of bone erosion in the hand and wrist in rheumatoid arthritis. Radiology 1965; 84: 204-14.

Graudal N. The natural history and prognosis of rheumatoid arthritis: association of radiographic outcome with process variables, joint motion and immune proteins. Scand J Rheumatol 2004; 118: 1-38.

Kaarela K, Kautiainen H. Continuous progression of radiological destruction in seropositive rheumatoid arthritis. J Rheumatol 1997; 24(7): 1285-7.

De Carvalho A, Graudal H, Jorgensen B. Radiologic evaluation of the progression of rheumatoid arthritis. Acta Radiol Diagn 1980; 21(1): 115-21.

Rajavashisth TB, Liao JK, Galis ZS, Tripathi S, Laufs U, Tripathi J, et al. Inflammatory cytokines and oxidized low density lipoproteins increase endothelial cell expression metalloproteinase. J Biol Chem 274: 11924–11929,1999. Ram M, Sherer Y, Shoenfeld Y. Matrix metalloproteinase-9 and autoimmune 89 77. Ann Intern Med 144:249.

Grundy, SM, Cleeman, JI, Daniels, SR. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112:2735. (2001 kriterlerinin UPDATE'i)

Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group The metabolic syndrome--a new worldwide definition. Lancet 2005; 366(9491): 1059-62.

The pathogenesis of atherosclerosis. In Braunwald E, Fauci A, Kasper D, Hauser S, Longo Dan L, Jameson Larry J (Eds.). Harrison’s principles of internal medicine15th ed. New York: Mc Graw Hill Co 2001; 1377-86.

World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications; Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva: WHO Department of Noncommunicable Disease Surveillance; 1999. http://www.diabetes.com.au/pdf/who_report.pdf

Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European group for the study of Insulin Resistance (EGIR) Diabet Med 1999; 16(5): 442-3.

World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications; Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva: WHO Department of Noncommunicable Disease Surveillance; 1999.

Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European group for the study of Insulin Resistance (EGIR) Diabet Med 1999; 16(5): 442-3.

Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-7.

Strazzullo P, Barbato A, Siani A. Diagnostic criteria for metabolic syndrome: a comparative analysis in an unselected sample of adult male population Metabolism Clinana Experimental 2008; 57: 355-61.

Einhorn D, Reaven GM, Cobin RH, Ford E, Ganda OP, Handelsman Y et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 2003; 9(3): 237-52.

International Diabetes Federation. Worldwide definition of the metabolic syndrome http://www.idf.org/webdata/docs/MetS_def_update2006.pdf

Onat A, Senocak M. Obesity in Turkish adults: prevalence, validity as a coronary risk factor and interrelation with other risk factors. Int J Ang 1995; 4: 94-8.

Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: An American Heart Association

/ National Heart, Lung and Blood Insitute Scientific Statement. Circulation 2005; 112: 2735-52.

Sanisoglu SY, Oktenli C, Hasimi A. Prevalence of metabolic syndrome-related disorders in large adult population in Turkey. BMC Public Health 2006; 6: 92-3.

Turkoglu Ç. [Editorial] Metabolik sendrom ve Koroner Kalp Hastalıgı Anadolu Kardiyol Derg 2004; 4: 17-8.

Iwai N, Tago N, Yasui N, Kokubo Y, Inamoto N, Tomoike H, Shioji K Genetic analysis of 22 candidate genes for hypertension in the Japanese population Journal of Hypertension 2004; 22(6): 1119-26.

Isıldak M, Sain Güven G, Gürlek A. Metabolik sendrom ve insulin direnci Hacettepe Tıp Dergisi 2004; 35: 96-9.

Haslam DW, James WP. Obesity. Lancet 2005; 366: 1197-209.

Waki H, Tontonoz P, Endocrine Functions of Adipose Tissue Annu Rev Pathol Mech Dis 2007; 2: 315-6.

Undurti N. Das, Metabolic Syndrome X: An Inflammatory Condition? Current Hypertension Reports 2004; 6: 66–73.

Allison DB, Heshka S. Toward an empirically derived typology of obese persons. Int J Obes 1991; 15: 741-54.

You T, Nicklas BJ. Effects of Exercise on Adipokines and the Metabolic Syndrome Current Diabetes Reports 2008; 8: 7-11.

Hamid YH, Rose CS, Urhammer SA, Glümer C,Kristiansen OP, et al Variations of the interleukin-6 promoter are associated with features of the metabolic syndrome in Caucasian Danes Diabetologia 2005; 48: 251–60.

Pearson T, Mensah AG, Alexander WR. Markers of inflammation and cardiovascular disease. Circulation 2003; 107: 499-511.

Ridker M, Hennekens CH, Buring JE. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women N Engl J Med 2000; 342: 836-43.

Timpson NJ. C-reactive-protein and it’s role in metabolic syndrome mendelian randomisation study Lancet 2005; 366: 1954-9.

Florez H. C-reactive protein is elevated in obese patients with the metabolic syndrome Diabetes Research and Clinical Practise 2006; 71: 92–100.

Anand SS, Razak F, Yi Q. C-reactive protein as a screening test for cardiovascular risk in a multi ethnic population. Arterioscler Thromb Vasc Biol 2004; 24: 1509–15.

Pearson T, Mensah AG, Alexander WR. Markers of inflammation and cardiovascular disease. Circulation 2003; 107: 499-511.

Hergenç G, Onat A. Toplumumuzda Ürik Asid Düzeyleri: Metabolik Sendromun bir belirleyicisi ve koroner hastalığın özellikle kadınlarda bir göstergesi. Türk Kardiyol Dern Ars 2004; 32: 71-81.

Taniguchi Y, Hayashi T, Tsumura K, Endo G, Fuji S, Okada K. Serum uric acid and the risk for hypertension and type 2 diabetes in Japanese men: the Osaka Health Survey. J Hypertens 2001; 19: 1209-15. Fang J, Alderman MH Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA 2000; 283: 2404-10.

Franse LV, Pahor M, Di Bari M. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J Hypertens 2000; 18: 1149-54.

Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999; 131: 7-13.

Coban E, Sari R, Ozdogan M, Akcit F. Levels of plasma fibrinogen and d-dimer in patients with impaired fasting glucose. Exp Clin Endocrinol Diabetes 2005; 113(1): 35- 7.

Rantapaae-Dahlqvist S, Solveig DJ. Lipoprotein(a), lipids and lipoproteins in patients with rheumatoid arthritis. Ann Rheum Dis 1991; 50: 366-8.

Bacon AP, Moots JR. Extra-articular rheumatoid arthritis. In: Koopman JW (ed). Arthritis and Allied Conditions. A Textbook of Rheumatology. Baltimore: Williams and Wilkins 1997; 1071-88.

Lorber M, Aviram M, Linn S, Scharf Y,Brook JG. Hipocholesterolaemia and abrnormal high density lipoprotein in rheumatoid arthritis. Br J Rheum 1985; 24: 250-5.

Lakatos J, Harsagyi A. Serum total, HDL, LDL-cholesterol and triglyceride levels in patients with rheumatoid arthritis. Clin Biochem 1988; 21: 93-6.

Chung CP, Oeser A, Solus® Cardiology An ASIR, single-chamber, rate-modulated pulse generator. See Pacemaker. JF, Avalos I, Gebretsadik T, Shintani A, et al. Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis. Atherosclerosis 2007; 29.

Karimi M, Mazloommzadeh S, Kafan S, Amirmoqhadami H Int J Rheum Dis. 2011 Aug;14(3):248-54. doi: 10.1111/j.1756-185X.2011.01595.x. Epub 2011 Mar 14.

Sidiropoulos PI, Karvounaris SA, Boumpas DT.Arthritis Res Ther. 2008;10(3):207. Epub 2008 May 8.

Svenson KL, Lundqvıst G, Wıde L, Hallgren K. Impaired Glucose Handing ın Actıve Rheumatoıd Arthritis: Relationship to The Secretion of Insulın and Counter Regulatory Hormones Metabolism 1987; 36: 940-3.

Paoliss G, Valentini G, Giugliano D, Marazzo G, Tirri R, Gallo M, et al: Evidence for Peripheral Impaired Hadnling in patients with Coonective Tissue Diseases Metabolism 1991; 40; 902-7.

Hanh-Hung Dao1,2, Quan-Trung Do3, Junichi Sakamoto1Dao. Arthritis Research & Therapy 2010, 12:R218.

Lim S. C-reactive protein level as an independent risk factor of metabolic syndrome in the Korean population & CRP as risk factor of metabolic syndrome. Diabetes Research and Clinical Practice 2005; 70: 126–33.

Anand SS, Razak F, Yi Q. C-reactive protein as a screening test for cardiovascular risk in a multi ethnic population. Arterioscler Thromb Vasc Biol 2004; 24: 1509–15.

Gonzalez-Gay MA, Gonzalez-Juanatey C, Martin J. Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Semin Arthritis Rheum 2005; 35: 8-17.

Laaksonen DE, Niskanen L, Nyyssönen K, Punnonen K, Tuomainen TP, Valkonen VP, Salonen R, Salonen JT. C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men. Diabetologia 2004;47(8): 1403-10. Epub 2004 Jul 28.

Akbal A, Selçuk B, Gürcan A, Kurtaran A, Ersöz M, Akyüz M. 2009, Cilt 24, Sayı 4, Sayfa(lar) 202-205.

Yoo TW, Sung KC, Shin HS, Kim BJ, Kim BS, Kang JH, et al. Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome. Circ J 2005; 69(8): 928-33.

Rathmann W, Funkhouser E, Dyer AR, Roseman JM. Relations of hyperuricemia with the various components of the insulin resistance syndrome in young black and white adults: the CARDIA study. Coronary Artery Risk Development in Young Adults. Ann Epidemiol 1998; 8(4): 250-61.

Imperatore G, Riccardi G, Iovine C, Rivellese AA, Vaccaro O. Plasma fibrinogen: a new factor of the metabolic syndrome. Diabetes Care 1998; 21: 649–54.

Ford ES. The metabolic syndrome and C-reactive protein, fibrinogen, and leucocyte count: findings from the Third National Health and Nutrition Examination Survey. Atherosclerosis 2003; 168: 351–8.

Rumley A, Emberson JR, Wannamethee SG, Lennon L, Whincup PH, Lowe GD. Effects of older age on fibrin D-dimer, C-reactive protein, and other hemostatic and inflammatory variables in men aged 60-79 years. J Thromb Haemost 2006; 4: 982-7.

Metabolic syndrome in rheumatoid arthritis patients over the age of 60- more than just an anti-inflammatory effect? A cross sectional study. Tracey E Toms 1,2, Vasileios F Panoulas1, Holly John1, Karen MJ Douglas1 and George D Kitas1,2 Received: 1 Apr 2009 Revisions requested: 11 May 2009 Revisions received: 22 Jun 2009 Accepted: 16

Jul 2009 Published: 16 Jul 2009 Arthritis Research & Therapy 2009, 11:R110 (doi:10.1186/ar2765)

Hurlimann D, Forster A, Noll G, Enseleit F, Chenevard R, Distler O, et al. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002; 106: 2184-7.

Wek RC, Anthony TG. Obesity: stressing about unfolded proteins. Nat Med 2010; 16(4): 374-6. No abstract available. Erratum in: Nat Med. 2010 May;16(5):607.

Hurt-Camejo E, Paredes S, Masana L, Camejo G, Sartipy P, Rosengren B, et al. Elevated levels of small, low-density lipoprotein, any organic compound that is composed of both protein and the various fatty substances classed as lipids, including fatty acids and steroids such as cholesterol. with high affinity for arterial matrix components in patients with rheumatoid arthritis: possible contribution of phospholipase A2 to this atherogenic atherogenic adj initiating, increasing, or accelerating atherogenesiatherogenic adjective Referring to the ability to initiate or accelerate atherogenesis—the deposition of atheromas, lipids, and profile. Arthritis Rheum 2001; 44: 2761-7.

Munro R, Morrison E, McDonald AG, Hunter JA, Madhok R, Capell HA. Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis. Ann Rheum Dis 1997; 56: 374-7.